Skip to content
20-F/A

Annual Report (Foreign)

INTELLIPHARMACEUTICS INTERNATIONAL INC.

0001654954-22-006198

← back to feed
Filed
May 9, 2022 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2021 · Nov 30, 2021 33.09M sh
Gross Profit FY 2021 · Nov 30, 2021 $0
Gross Profit FY 2021 · Nov 30, 2020 $1.4M
Gross Profit FY 2021 · Nov 30, 2019 $3.45M
Cash And Equivalents FY 2021 · Nov 30, 2020 $202.05K
Total Liabilities FY 2021 · Nov 30, 2020 $9.7M
Current Assets FY 2021 · Nov 30, 2020 $1.48M
Total Assets FY 2021 · Nov 30, 2020 $3.39M
Capex FY 2021 · Nov 30, 2019 $14.47K
Operating Cash Flow FY 2021 · Nov 30, 2019 −$6.66M
Sga Expense FY 2021 · Nov 30, 2019 $4.17M
Rd Expense FY 2021 · Nov 30, 2019 $6.61M
Net Income FY 2021 · Nov 30, 2019 −$8.08M
Operating Income FY 2021 · Nov 30, 2019 −$7.83M
Revenue FY 2021 · Nov 30, 2019 $3.48M
Stockholders Equity FY 2021 · Nov 30, 2018 $4.1M